In conclusion, the present report demonstrated that HA-CD44/RHAMM signaling plays a pivotal role in the proliferation and survival of NSCLC cells and provides a strong rationale for the clinical use of triptolide to mitigate lung cancer exhibiting activation of HA-CD44/RHAMM signaling axis. Here, CD44 is linked to non-small cell lung carcinoma.